Aptivus in the hotseat. Excerpts from the FDA hearings.
Huff
Bob
B
D017277:Drug Approval / Q000331:legislation & jurisprudence*; D004338:Drug Combinations; D024882:Drug Resistance, Viral; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011753:Pyrones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D019438:Ritonavir / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013449:Sulfonamides; D014481:United States; D014486:United States Food and Drug Administration
D004338:Drug Combinations; D017320:HIV Protease Inhibitors; D011725:Pyridines; D011753:Pyrones; D013449:Sulfonamides; D019438:Ritonavir; C107201:tipranavir